Evidence mapPaperPMID 20634174Full record

Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.

Ather Ali, Yingying Ma, Jesse Reynolds, John Pierce Wise, Silvio E Inzucchi, David L Katz

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00067626 (Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00067626 phase2completednot on this map

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

TypeinterventionalSponsorGriffin HospitalRan2005 to 2009Enrolled60ConditionsObesity, Pre-diabetes, Insulin Resistance, Impaired Glucose ToleranceArmsChromium
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. The Impact of Chromium Supplementation on Blood Pressure: A Systematic Review and Dose-Response Meta‑Analysis of Randomized‑Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2021
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Hypoxia-inducible factors and diabetes.The Journal of clinical investigation · 2020
    Review
  13. Article
  14. Trace Elements in Human Nutrition (II) - An Update.International journal of preventive medicine · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ather AliPrevention Research Center, Yale University School of Medicine, Derby, Connecticut 06418, USA.
Yingying Ma
Jesse Reynolds
John Pierce Wise
Silvio E Inzucchi
David L Katz
Yale University · USUniversity of Southern Maine · US

Funding

Particulate Cr(VI) Toxicology in Human Lung Epithelial Cells and FibroblastsR01ES016893 · NIEHS · UNIVERSITY OF LOUISVILLE · PI John Pierce Wise · 2021 to 2021
$494k
Chromium Effects in Imparied Glucose ToleranceR21AT001332 · GRIFFIN HEALTH SRVS CORP-GRIFFIN HOSP · 2003 to 2004
$309k
Research Training in Integrative MedicineF32AT002667 · GRIFFIN HEALTH SRVS CORP-GRIFFIN HOSP · 2005 to 2005
$60k
Meeting Community Needs Across the Prevention SpectrumU48DP000053 · YALE UNIVERSITY · 2004 to 2005
NCCDPHP CDC HHS U48 DP000053NCCIH NIH HHS F32 AT002667NCCIH NIH HHS L30 AT004887NCCIH NIH HHS R21 AT001332NCCIH NIH HHS R21 AT1332NCRR NIH HHS UL1 RR024139NIEHS NIH HHS R01 ES016893
6 · The paper itself

Abstract

objectiveTo investigate the effects of daily chromium picolinate supplementation on serum measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes mellitus.

methodsWe conducted a randomized, double-blind, placebo-controlled, modified cross-over clinical trial with 6-month sequences of intervention and placebo followed by a 6-month postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure, endothelial function, hemoglobin A1c, lipids, and urinary microalbumin.

resultsFifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05).

conclusionsChromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk.

Indexed as

AdultAgedBlood GlucoseChromiumDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucose IntoleranceGlucose Tolerance TestHumansInsulin ResistanceMaleMiddle AgedBlood GlucoseChromium

Identifiers

PMID20634174
PMCPMC3118091
OpenAlexW2069986293

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.